home / stock / etnb / etnb articles

ETNB Articles, 89bio Inc.

Stock Information
Company Name: 89bio Inc.
Stock Symbol: ETNB
Market: NYSE
Menu
ETNB ETNB Quote ETNB Short ETNB News ETNB Articles ETNB Message Board
Get ETNB Alerts

News, Short Squeeze, Breakout and More Instantly...
89bio to Participate in the BofA Securities 2024 Health Care Conference | Benzinga

SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development...
89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH | Benzinga

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development...

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors | Benzinga

SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the developme...

Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying | Benzinga

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confide...
89bio to Participate in the Leerink Partners Global Biopharma Conference | Benzinga

SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the developme...

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quar...

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference | Benzinga

SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the developmen...
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development | Benzinga

RBC Capital Markets downgraded 89Bio Inc (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on developing and commerc...

Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session | Benzinga

U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CX...

89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease | Benzinga

89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in...
Next 10